SQZ Biotechnologies Net Profit Margin 2020-2022 | SQZ

SQZ Biotechnologies net profit margin from 2020 to 2022. Net profit margin can be defined as net Income as a portion of total sales revenue.
SQZ Biotechnologies Net Profit Margin Historical Data
Date TTM Revenue TTM Net Income Net Margin
2022-03-31 $0.03B $-0.07B -296.00%
2021-12-31 $0.03B $-0.07B -251.85%
2021-09-30 $0.02B $-0.07B -435.29%
2021-06-30 $0.02B $-0.06B -355.56%
2021-03-31 $0.02B $-0.06B -289.47%
2020-12-31 $0.02B $-0.05B -255.00%
2020-06-30 $0.02B $-0.03B -181.25%
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.092B $0.027B
SQZ Biotechnologies Company is a clinical-stage biotechnology company. It develops transformative cell therapies for patients with cancer, infectious diseases and other serious conditions. The company's prime product candidate consist SQZ-PBMC-HPV which is in clinical stage. SQZ Biotechnologies Company is based In Watertown, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $161.724B 9.84
Bio-Rad Laboratories (BIO.B) United States $15.121B 32.79
QIAGEN (QGEN) Netherlands $10.093B 15.93
Biohaven Pharmaceutical Holding (BHVN) United States $9.948B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.434B 0.00
Emergent Biosolutions (EBS) United States $1.592B 6.82
Arcus Biosciences (RCUS) United States $1.327B 33.64
Myovant Sciences (MYOV) United Kingdom $0.961B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.483B 0.00
Gelesis Holdings (GLS) United States $0.357B 0.00
Zymeworks (ZYME) Canada $0.336B 0.00
Ambrx Biopharma (AMAM) United States $0.154B 0.00
Enzo Biochem (ENZ) United States $0.117B 24.00